Published on August 27, 2014
Tris Pharma Receives NJBIA Award for Excellence
Tris Pharma Selected as an Award Winner in the New Jersey Business & Industry Association's 2014 Awards for Excellence
MONMOUTH JUNCTION, N.J., August 27, 2014; -
Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies, today announced that it has been selected as an award winner in the New Jersey Business & Industry Association’s 2014 Awards for Excellence competition in the Business Expansion category. Finalists were selected by an independent panel of judges from SCORE (Counselors to America’s Small Business) and NJBIA member company volunteers. Award winners will be honored at a gala event to be held on October 15, 2014 at the Pines Manor in Edison, New Jersey.
The Business Expansion Award is presented to companies that have contributed to the state’s economic growth through the expansion of their business. Tris was selected for its significant growth in the creation of new jobs over the past three years.
“We’re thrilled to be an award winner for the NJBIA’s 2014 Awards for Excellence competition” said President & CEO Ketan Mehta. “Tris has been part of the New Jersey landscape for 14 years and we believe in supporting the prosperity of our local communities; on behalf of myself and our employees I’d like to thank the community for their support and the Awards for Excellence Committee for selecting Tris to receive this award."
Tris has several proprietary solubilization and bioavailability enhancing technologies as well as several generic extended release solid dosage products in development, under FDA review and in the market. Tris’ proprietary technologies and developed products are the catalyst for its’ dramatic growth over the past three years culminating in a 24-hour operation and the addition of almost 250 jobs
About Tris Pharma:
Tris Pharma is a specialty pharmaceutical company focused on the research and development of technologies driven products. Tris has pioneered the delivery of sustained release in the liquid, chewable/ODT and strip dosage forms so patients do not have to swallow a pill. Tris' Nobuse technology provides abuse deterrence for opioids and other abuse-prone drugs. Tris' R&D and manufacturing facilities are located in Monmouth Junction, New Jersey, USA. For more information, please visit http://www.trispharma.com